Michael Khodadoust, MD, PhD, of the Stanford University School of Medicine, Stanford, CA, discusses the future of checkpoint inhibitors in cutaneous lymphoma. He highlights the follow-up trial to CITN-10, CITN-13, which investigated pembrolizumab plus interferon-gamma 1b in relapsed/ refractory mycosis fungoides or Sézary syndrome (NCT03063632). He calls for the development of predictive markers of pembrolizumab response for cutaneous lymphoma, as well as research into synergist agents to improve response rates. This video was recorded at the European Organisation for the Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force (CLTF) 2018 Congress, held in St. Gallen, Switzerland
Future directions for checkpoint inhibitors in cutaneous lymphoma treatment
